Objective The diagnosis of amyloidosis still relies on
Introduction
Amyloidosis is a disorder characterized by deposition in the extracellular tissues of fibrils composedof various proteins, such as amyloid light chains (AL) in primary (AL) amyloidosis, amyloid A (AA) in secondary (AA) amyloidosis, and p2-microglobulin in dialysis-associated amyloidosis. These fibrils have a predominantly antiparallel p-pleated sheet configuration, and can be identified in biopsy specimens both by their characteristic appearance on electron microscopy, and by their ability to bind Congo red and thioflavine T (1) . The diagnosis of amyloidosis still relies on biopsy and the pathological demonstration of typical deposits, with few other indicators available to suspect or support the diagnosis of this disease. Since biopsy is an invasive examination, a noninvasive and sensitive test for amyloidosis is needed (2, 3) . The presence of a paraprotein in serum or urine is useful in ALamyloidosis but it is also commonin patients with multiple myelomairrespective of the presence of amyloidosis. Hepatocyte growth factor (HGF) was originally purified as a potent mitogen of primary cultured hepatocytes (4). HGF acts on a variety of epithelial cells in multiple ways, as an activator of mitogenesis, motogenesis, and morphogenesis (5-7).
Both HGFand its receptor c-met exhibit cell type-specific expression, with HGFbeing predominantly produced by mesenchymal cells, whereas the c-met gene is expressed in epithelial cells. This pattern of mesenchymalsources adjacent to epithelial targets suggests that HGFis a prime candidate for mediating mesenchymal-epithelial interactions during the processes of embryogenesis, tissue repair, and organ regeneration (8) . With respect to the kidney, HGFstimulates the proliferation of renal epithelial cells, and is a potent renotrophic factor involved in regeneration after acute renal failure (9-1 2). There have been no previous investigations of the relationship between amyloidosis and HGF.In the present study, we measured the serum HGFlevel in patients with amyloidosis and investigated its usefulness for making diagnosis of this disease. 
Subjects and Methods
The subjects were 18 patients whowere diagnosed as having amyloidosis by biopsy of the kidney or gastrointestinal tract. Their clinical characteristics are shownTable 1. Amyloidosis was diagnosed based on positive Congored or Dylon staining. The differential diagnosis of ALand AAamyloidosis was done using anti-human lambda light-chain antibody and anti-amyloid A protein or the clinical features. All patients had proteinuria and/or renal dysfunction, but did not have serious infection, acute renal failure, or severe liver dysfunction. Since all patients had obvious renal dysfunction, we also measured the serum HGFlevel in 47 patients with chronic glomerulonephritis (CGN), 32 patients on hemodialysis, and 24 healthy volunteers. All of the dialysis patients had a short duration of hemodialysis (less than 10 years) and the cause of renal failure was primary glomerulonephritis. The serum HGFlevel was measured using an HGFELISA kit (Otsuka Assay Co., Ltd., Tokyo), which is widely employed for the diagnosis of fulminant hepatitis in Japan. This kit has an antihuman HGFmonoclonal antibody as the solid phase and an antihuman HGFrabbit polyclonal antibody as the liquid phase. The monoclonal antibody only reacts with a disulfide-linked heterodimer of the a-and p-chains. The reference serum HGFlevel for this kit was 0. 19±0.05 ng/ml and the serum HGFlevel that we found in our 24 healthy volunteers was 0.20±0.04 ng/ml. This was the same as had been obtained using the kit in fundamental studies. The detection limit of the kit was 0. 1 ng/ml. To confirm the reproducibility of serum HGF data, blood samples were collected at different days from some of the patients with amyloidosis, and the reproducibility of measurement was shown to be good (Table 2) . Data were subjected to statistical analysis using analysis of variance and further analysis was performed using Fisher's protected least significant difference test. Wealso used MannWhitney U test to compare two groups. Results were expressed as the mean±SDand the level of significance was set at £<0.05. Figure 1 shows the serum HGFlevels in the healthy volunteers, CGNpatients, hemodialysis patients, and the patients with amyloidosis. The CGNpatients were divided into two groups according to their serum creatinine levels. In patients with amyloidosis, serum HGFwas significantly increased compared with the level in healthy volunteers, patients with mild CGN(serum creatinine level <3.0 mg/ml), patients with severe CGN(serum creatinine level^3.0 mg/ml), and hemodi- alysis patients (2.0212.62 ng/ml versus 0.20±0.04 ng/ml, 0.21±0.06 ng/ml, 0.29±0.09 ng/ml, and 0. 18±0.07 ng/ml, respectively, p<0.0001). The mean HGFlevel of the amyloidosis patients was 10-fold higher than in the other groups. The serum HGFlevel of patients with severe CGNwas higher than those of healthy volunteers and patients with mild CGN, but the difference was not significant. Whenthe normal HGFlevel was set at less than 0.28 ng/ml (mean +2 SD for the healthy volunteers), the sensitivity of serum HGFassay for the diagnosis of amyloidosis was 94% and the specificity was 100%. An extremely high serum HGF level (^0.39 ng/ml) was found in 14 out of 18 patients with amyloidosis. In the diagnosis of fulminant hepatitis, the normal range of this kit is wider than usual and a level^0.39 ng/ml (mean +4SD) is classified as abnormal, with the sensitivity and specificity being 78% and 100%, respectively. A high level of serum HGF(^0.39 ng/ml) was recognized in 2 out of 47 CGNpatients, being 0.42 ng/ml in both cases. Figure 2 shows the serum HGFlevels of the patients with AL amyloidosis and AAamyloidosis. There was no significant difference between the two groups. However, the serum HGF level of amyloidosis patients who died within 1 year of measurement was significantly higher than that of patients who lived for more than 1 year (2.83±2.85 ng/ml versus 0.49±0.26 ng/ml, p<0.01) (Fig. 3) .
Results

Discussion
It is difficult to diagnose amyloidosis because there are few specific symptoms. ALamyloidosis should be considered in the differential diagnosis of all patients over the age of 40 who have otherwise unexplained marked severe proteinuria ( 1 3, 14) .
In patients with rheumatoid arthritis, marked severe proteinuria can be induced by membranousnephritis due to gold, penicillamine, or AAamyloidosis. Biopsy is necessary to make a definite diagnosis of this disease, but it cannot be performed easily because of the invasiveness of the procedure. It wouldbe very useful if this disease could be diagnosed by a convenient noninvasive technique, such as a blood test or imaging method, but no such technique has been available. Therefore, amyloidosis is often diagnosed at a very advanced stage. The prognosis of ALamyloidosis is very poor and the survival time after diagnosis is short. Furthermore, there are manypatients who
Internal Medicine Vol. 39, No. 9 (September 2000) are only diagnosed at autopsy. Treatment of this disease is often difficult, because there are few specific therapies available. However, it has been reported that the prognosis of amyloidosis can be improved by appropriate early treatment, for example using melphalan (15) , colchicine (15, 16) , and 4'-iodo-4'-deoxydoxorubicin (17) . Thus, there has been a growing demand for the development of a specific noninyasive diagnostic technique. The present study showed that the serum HGFlevel was significantly elevated in both AL and AAamyloidosis patients irrespective of the precursor protein, and HGFwas shown to be a very useful indicator for suspecting amyloidosis. The mean HGFlevel was 10-fold higher compared with that in healthy controls. Some previous studies have detected an increased serum HGFlevel in renal diseases (18) (19) (20) . In CGNpatients, the serum HGFlevel was shown to be high compared with that of healthy controls, but the difference was small and not significant. In patients with rheumatoid arthritis, it was reported that the HGFlevel in synovial fluid was significantly increased, while serum HGFwas not high (21, 22) . In patients with multiple myeloma, it was reported that the HGFlevel at the time of diagnosis was significantly high, while serum HGFdecreased by the treatment to nearly the normal level (23) . Our patient with multiple myeloma (case ll) was well controlled by the treatment. The elevation of the meanserum HGFlevel in our patients with amyloidosis was extreme and was unlike that seen in other diseases. Evenwhenthe normal range was set at 0.39 ng/ml (mean +4SD), the sensitivity of this examination was still 78%and the specificity was 100%. In addition, the serum HGFlevel may become a prognostic indicator. The serum level in patients who died within 1 year was significantly higher than that in patients whohad a longer survival. Although this was a limited study, we clearly showed that the serum HGFlevel is often abnormally high in patients with amyloidosis. The measurement of serum HGFmust be reproducible if HGFis to be used for diagnosing amyloidosis; in the present study the measurements were shownto be highly reproducible when investigating some amyloidosis patients. There have been no previous reports on the relationship between HGFand amyloidosis. HGFis mainly produced by mesenchymal cells and macrophagesin response to strong stimulation by IL-ip and TNF-oc (24) . Infection is one of the important cause that stimulates the production of IL-lp and TNF-oc. Serum HGFlevels have been reported to increase in acute infection (25) , but the extent of the increase is less than in amyloidosis; most of our patients had no obvious infection. The present study showed that the serum HGFlevel was elevated irrespective of the amyloid precursor protein in the patients with ALor AAamyloidosis. These results suggested that HGFmay increase as a result of extracellular amyloid deposition leading to the stimulation of macrophages and mesenchymal cells and the elevation of serum HGFmay be correlated with the amountor extension of amyloid. There is also a possibility that HGFis concerned with the pathogenesis of amyloid deposition. The relationship between amyloidosis and HGFis still unclear. However, it appears useful to measure serum HGF as an indicator for the diagnosis of amyloidosis and may be a prognostic indicator.
